## Blood and Marrow Transplant Clinical Trials Network

	SCD Events of Special Interest Form (ESI)
So amont (DDOTSEC), A	Web Version: 1.0; 4.00; 06-05-17
Segment (PROTSEG): A Visit Number (VISNO):	
D	
Date of last contact: (ESICNTDT)	(mm/dd/yyyy)
	et of any of the below listed Sickle Cell Disease Events of Special Interest (SCD-EOSI) after screening evaluations are SCD-EOSI returns to the patient's baseline. Therefore, multiple occurrences of the same or several SCD-EOSIs may be
Since the date of the last study	visit indicate if any of the following have occurred:
Did the patient experience pulmonary hypertension during this assessment period?(ESIPULM)	☐ 1 - Yes ☐ 2 - No
2. Was this a new episode of pulmonary hypertension during this assessment period? (ESINPULM)	☐ 1 - Yes ☐ 2 - No
Date of new episode of pulmonary hypertension:(ESINPUDT)	(mm/dd/yyyy)
<ol> <li>How was pulmonary hypertension diagnosed?(ESIPDIAG)</li> </ol>	1 - Right Heart Catheterization 2 - Echocardiogram
<ol><li>Was an intervention required to treat pulmonary hypertension?(ESINTREQ)</li></ol>	☐ 1-Yes ☐ 2-No
6. Select treatment in itia ted:(ESIPUTRM)	1 - Sildenafil
	2 - Bosentan 3 - Oxygen with RBC Transfusions
	9 - Other
Other, specify:(ESITRMSP)	
7. Did the patient experience a new onset of a significant cerebrovascular event (stroke, transient ischemic attack, or seizure) during this assessment period?(ESICEREB)	1 - Yes 2 - No
<ol> <li>How many times did the patient experience a new onset of stroke during this assessment period?(ESISTRKT)</li> </ol>	(xx) time(s)
<ol> <li>How many times did the patient experience a new onset of transient ischemic attack (T IA) during this assessment period?(ESITIAT)</li> </ol>	(xx) time(s)
<ol> <li>How many times did the patient experience a new onset of seizure during this assessment period?(ESISEIZT)</li> </ol>	(xx) time(s)
<ol> <li>Date of first occurrence of any significant cerebrovascular event during this assessment period: (ESICERDT)</li> </ol>	(mm/dd/yyyy)
12. Did the patient experience renal function compromise (proteinuria or increased creatinine grades ≥ 2 per CTCAE version 4.0) during this assessment period? (ES IRENL)	☐ 1 - Yes ☐ 2 - No
<ol> <li>Did the patient experience a new onset of proteinuria during this assessment period? (ESIPROT)</li> </ol>	☐ 1 - Yes ☐ 2 - No
14. Date of new onset of proteinuria: (ESIPRODT)	(mm/dd/yyyy)
15. Did the patient experience a new onset of increased creatinine (grades ≥2 per CTCAE version 4.0) during this assessment period? (ESINCREA)	1 - Yes 2 - No
16. Date of new onset of increased creatinine: (ESICREDT)	(mm/dd/yyyy)
17. Did the patient experience a new onset of avascular necrosis of the hip or shoulder during this assessment period?(ESINECR)	☐ 1 - Yes ☐ 2 - No

18.	Did the patient experience a new onset of leg ulceration during this assessment period? (ESIULCR)	1 - Yes 2 - No
19.	Did the patient experience a new onset of acute chest syndrome requiring hospitalization during this assessment period?(ESIACS)	1 - Yes 2 - No
	20. How many times was the patient hospitalized for a cute chest syndrome during this assessment period?(ESIACST)	(xx) time(s)
	21. Date of first occurrence of acute chest syndrome requiring hospitalization during this assessment period: (ESIACSDT)	(mm/dd/yyyy)
22.	Did the patient experience a new onset of painful vaso-occlusive crisis requiring hospitalization OR parenteral opioid drugs in the outpatient setting during this assessment period?(ESIVOC)	1 - Yes 2 - No
	23. How many times was the patient hospitalized for painful vaso-occlusive crisis during this assessment period?(ESIVOCHT)	(xx) time(s)
	24. How many times were parenteral opioid drugs required for the painful vaso-occlusive crisis in the outpatient setting during this assessment period?(ESIVOCOT)	(xx) time(s)
	25. Date of first occurrence of painful vaso-occlusive crisis requiring hospitalization OR parenteral opioid drugs in the outpatient setting during this assessment period: (ESIVOCDT)	(mm/dd/yyyy)
26.	Did any of the events reported above lead to an advanced care intervention or Intensive Care Unit admission/transfer as outlined in the AE reporting section of chapter 4 of the protocol? (ESIAEICU)	1 - Yes 2 - No 3 - Not Applicable
	Specify event(s):(ESIAESP)	
	Comments:(ESICOMM)	